Business Context and Reporting Period
This Form 8-K Current Report was filed by Praxis Precision Medicines, Inc. on May 25, 2021. The filing reports the immediate appointment of a new Chief Financial Officer and related compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms:
- Base Salary: $425,000 annual base salary for fiscal year 2021 (prorated based on start date).
- Bonus Target: Eligible for an annual bonus with a target amount equal to 40% of base salary.
- Equity Grant: Option to purchase 200,000 shares of common stock.
- Vesting Schedule: 25% vests on the one-year anniversary; the remaining 75% vests in 36 equal monthly installments.
Material Changes
The primary material change reported is the leadership transition in the finance function:
- Appointment: Timothy E. Kelly was appointed Chief Financial Officer, Treasurer, and Principal Financial Officer, effective May 25, 2021.
- Interim Role Conclusion: Lauren Mastrocola, who served as interim Principal Financial Officer, ceased these responsibilities effective the same date but remains Vice President of Finance and Principal Accounting Officer.
Outlook, Risks, and Management Commentary
The filing includes no forward-looking guidance, risk factors, or management commentary regarding business operations or financial outlook. It notes that Mr. Kelly brings prior experience as CFO of Foundation Medicine, Inc., and extensive finance roles at the Roche Group and Genentech. The company confirmed there are no undisclosed arrangements regarding Mr. Kelly's appointment.
Investor Verification Checklist
- Verify the vesting commencement date for the 200,000 share option grant to Mr. Kelly.
- Review the standard form of amended and restated employment agreement referenced in the filing for termination provisions.
- Confirm the exact prorated salary amount for the remainder of fiscal year 2021.
- Check subsequent filings for any changes to the interim finance leadership structure.